Narsoplimab (OMS721), a Masp-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

MLA

Olaf Penack, et al. “Narsoplimab (OMS721), a Masp-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA).” Transplantation and Cellular Therapy, vol. 27, Mar. 2021, pp. S24–26. EBSCOhost, https://doi.org/10.1016/s2666-6367(21)00052-x.

APA

Olaf Penack, Nelson Leung, Michael Scordo, Mehdi Hamadani, Alessandro Rambaldi, Jaap Jan Boelens, Rafael F. Duarte, Sebastian Mayer, Miguel-Angel Perales, Sergio Giralt, Samer K. Khaled, Wlodzimierz Mendrek, Jeffery C Laurence, Vincent T. Ho, Jameela Sathar, Mitchell S. Cairo, Richard E. Champlin, & Sumithira Vasu. (2021). Narsoplimab (OMS721), a Masp-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA). Transplantation and Cellular Therapy, 27, S24–S26. https://doi.org/10.1016/s2666-6367(21)00052-x

Chicago

Olaf Penack, Nelson Leung, Michael Scordo, Mehdi Hamadani, Alessandro Rambaldi, Jaap Jan Boelens, Rafael F. Duarte, et al. 2021. “Narsoplimab (OMS721), a Masp-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA).” Transplantation and Cellular Therapy 27 (March): S24–26. doi:10.1016/s2666-6367(21)00052-x.